Sector Expert: Christopher James

Corcept Therapeutics Inc.

Image: Christopher James

Christopher James, M.D., is Director of Investor Relations with Corcept Therapeutics. Previously he was Managing Director and Equity Analyst at Ladenburg Thalmann, focusing on life sciences companies with strong growth potential and developing novel agents for serious diseases including cancer and infectious, neurological, inflammatory, metabolic and cardiovascular diseases. He was previously a senior equity research analyst at FBR & Co., Brinson Patrick, Rodman & Renshaw and MLV & Co. Prior to joining Brinson Patrick, Dr. James was chief medical officer and senior vice president of medical affairs at Retrophin, a biotechnology company focused on developing therapeutics for rare and devastating diseases. While at Retrophin, he played a pivotal role in the study design and subsequent acceptance of an investigational new drug application with the cardiorenal division of the FDA to initiate a Phase 2 clinical study in a rare kidney disease called focal segmental glomerulosclerosis. Dr. James has prior buyside experience working at Trivium Capital Management and MSMB Capital Management. Dr. James trained in neurological surgery at Cornell-New York Hospital and Memorial Sloan Kettering Cancer Center. He obtained a medical degree from Yale University School of Medicine and a bachelor of science in biology from Cornell University.



Recent Quotes

"We are initiating coverage of BOTA with an Outperform rating."

— Christopher James, FBR & Co. (12/23/15)
more >

"We are initiating coverage of AST with an Outperform rating."

— Christopher James, FBR & Co. (11/18/15)
more >

"There is extraordinary upside potential in STEM."

The Life Sciences Report Interview with Christopher James (12/4/14)
more >

"You have lots of shots on goal with RNN."

The Life Sciences Report Interview with Christopher James (12/4/14)
more >

"RNN ended Q2/14 with $38.3M cash, providing it sufficient runway into H2/16."

— Christopher James, Brinson Patrick Securities Corporation (9/8/14)
more >

"STEM will be first to initiate a controlled Phase 2 study using human neural stem cells."

— Christopher James, Brinson Patrick Securities Corporation (9/8/14)
more >

"RNN has sufficient runway into H2/16: we reiterate our Outperform."

— Christopher James, Brinson Patrick Securities Corporation (8/27/14)
more >

"Initial interim data from the Phase 1/2 study with STEM's HuCNS-SC cells in geographic atrophy age-related macular degeneration were extraordinarily encouraging."

The Life Sciences Report Interview with Christopher James (7/31/14)
more >



Due to permission requirements, not all quotes are shown.